Año 2024 / Volumen 116 / Número 7
Carta
Treatment of steroid-refractory immune checkpoint inhibitor-induced intestinal pseudo-obstruction with infliximab

383-384

DOI: 10.17235/reed.2023.9796/2023

Cong Dai, Yu-Hong Huang,

Resumen
Immune checkpoint inhibition therapy using targeted monoclonal antibodies is a relatively new therapeutic approach for patients with several cancer types including non-small cell lung cancer1. Targeted monoclonal antibodies based drugs can activate anti-tumor immunity by blocking immune checkpoint receptors (CTLA-4, PD-1 receptor and its ligand PD-L1), in order to restore T-cell effector function2,3. However, the use of immune checkpoint inhibitors can lead to a unique side effect profile termed as immune-related adverse events (irAEs). Loss of T-cell inhibition results in an enhanced immune response driven by T-cell activation and is capable of inducing an autoimmune-related inflammation in normal tissue as a consequence of impaired self tolerance4. These irAEs can potentially involve every organ system including gastrointestinal, dermatologic, hepatic, and endocrine toxicities. For example, Fernandez-Gordon Sanchez et al reported a patient with immune-mediated colitis and nonimmune-mediated cholestasic injury induced by pembrolizumab that was successfully treated with Ustekinumab5. We report a steroid-refractory case of lung adenocarcinoma patient with an unusual irAE (intestinal pseudo-obstruction) during the treatment with immune checkpoint inhibitors that could be successfully managed by the administration of infliximab.
Nuevo comentario
Comentarios
No hay comentarios para este artículo.
Bibliografía
1. Gettinger S, Rizvi NA, Chow LQ, et al. Nivolumab monotherapy for first-line treatment of advanced non-small-cell lung cancer. J Clin Oncol 2016; 34: 2980-2987.
2. Friedman CF, Proverbs-Singh TA, Postow MA. Immune-related adverse effects of immune checkpoint inhibitors: a review. JAMA Oncol 2016; 2: 1346-1353.
3. Marrone KA, Brahmer JR. Using immune checkpoint inhibitors in lung cancer. Oncology 2016; 30: 713-721.
4. Freeman-Keller M, Kim Y, Cronin H, et al. Nivolumab in resected and unresectable metastatic melanoma: characteristics of immune-related adverse events and association with outcomes. Clin Cancer Res 2016; 22: 886-894.
5. Fernandez-Gordon Sanchez FM, Gomez-Dominguez E, Paredes Ruiz D, et al. Ustekinumab for corticodependent immune-mediated colitis by pembrolizumab, an alternative for patients with concomitant liver injury. Rev Esp Enferm Dig 2022; 6: 356-357.
Artículos relacionados

Editorial

Uso seguro de los inhibidores de la bomba de protones

DOI: 10.17235/reed.2023.9834/2023

Carta

Cuando la obstrucción intestinal no es quirúrgica

DOI: 10.17235/reed.2023.9630/2023

Carta

Chronic intestinal pseudo-obstruction in MELAS

DOI: 10.17235/reed.2020.7099/2020

Instrucciones para citar
Dai C, Huang Y. Treatment of steroid-refractory immune checkpoint inhibitor-induced intestinal pseudo-obstruction with infliximab. 9796/2023


Descargar en un gestor de citas

Descargue la cita de este artículo haciendo clic en uno de los siguientes gestores de citas:

Métrica
Este artículo ha sido visitado 1554 veces.
Este artículo ha sido descargado 63 veces.

Estadísticas de Dimensions


Estadísticas de Plum Analytics

Ficha Técnica

Recibido: 21/06/2023

Aceptado: 27/06/2023

Prepublicado: 14/07/2023

Publicado: 08/07/2024

Tiempo de prepublicación: 23 días

Tiempo de edición del artículo: 383 días


Compartir
Este artículo aun no tiene valoraciones.
Valoración del lector:
Valora este artículo:




Asociación Española de Ecografía Digestiva Sociedad Española de Endoscopia Digestiva Sociedad Española de Patología Digestiva
La REED es el órgano oficial de la Sociedad Española de Patología Digestiva, la SociedadEspañola de Endoscopia Digestiva y la Asociación Española de Ecografía Digestiva
Política de cookies Política de Privacidad Aviso Legal © Copyright 2025 y Creative Commons. Revista Española de Enfermedades Digestivas